VEGFA and neoplasm: In support of this view, the pharmacological blockade of A2B receptors with the selective antagonist PSB1115, reduces the release of VEGF and the number of tumor-infiltrating MDSCs in a mouse melanoma model, thus corroborating the pro-angiogenic and immunosuppressive effects of this receptor subtype [106].